IP Library › Granted Patent US 12,558,382
Granted Patent B2
US 12,558,382 · App. 18/460,217 · Granted Feb 24, 2026

Repair and/or reconstruction of invertebral discs

Inventor: Peter Ghosh (Fairlight, AU)
Assignee: MESOBLAST, INC.
A61K35/545A61K9/4866A61K31/726A61K31/727A61K31/728A61K31/737A61K35/12A61K35/28A61K38/14A61K47/36A61L27/3834A61L27/3856A61L27/52C12N5/0663A61K2035/124A61K2300/00A61L2430/38C12N2501/905
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,558,382
App. No.
18/460,217
Granted
Feb 24, 2026
Kind
B2
Abstract

This invention relates to a method for repair and reconstitution of invertebral discs in a subject which involves administration of STRO-1 + multipotent cells. The method of the invention is useful in the treatment of spinal conditions characterized by degeneration of the invertebral disc.

Claims (5)

1 . A method for treating low back pain caused by a degenerated intervertebral disc in a human subject, the method comprising administering into the intervertebral disc space of the degenerated intervertebral disc a therapeutically effective amount of a composition comprising a culture-expanded population of allogeneic human cells enriched for non-hematopoietic, STRO-1 + , TNAP + multipotential cells and/or progeny cells thereof, wherein the population of human cells is substantially free of CD34 + cells, wherein the administration of the composition restores the degenerated intervertebral disc by secreting paracrine factors into the disc space, and wherein the administration is not into the nucleus pulposus.

2 . The method according to claim 1 further comprising administering into the intervertebral disc space a glycosaminoglycan (GAG).

3 . The method according to claim 2 , wherein the GAG is selected from the group consisting of hyaluronic acid (HA), chondroitan sulfate, dermatan sulfate, keratin sulfate, heparin, heparin sulfate, and galactosaminoglycuronglycan sulfate (GGGS).

4 . The method according to claim 1 , wherein at six months after the administration, the disc height index (DHI) of the subject's intervertebral disc is greater than the DHI of the subject's intervertebral disc prior to the administration.

5 . The method according to claim 1 , comprising administration into the annulus fibrosus (AF).

Assignments (2)
CHANGE OF NAME Recorded Sep 20, 2023
From: ANGIOBLAST SYSTEMS, INC.
To: MESOBLAST, INC.
Reel/Frame 064969/0873 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2023
From: GHOSH, PETER
To: ANGIOBLAST SYSTEMS, INC.
Reel/Frame 064842/0902 →
Continuity (5)
Continuation 17876445 · Jul 28, 2022
Continuation 14504308 · Oct 1, 2014
Continuation 13000721
Provisional Application 61133111 · Jun 25, 2008
Related Publication 20240075075A1 · Mar 7, 2024
References Cited (74)
US 5486539A · Caplan et al. · 1996 [cited by applicant]
US 6087113A · Caplan et al. · 2000 [cited by applicant]
US 8858932B2 · Ghosh · 2014 [cited by applicant]
US 9381216B2 · Ghosh · 2016 [cited by applicant]
US 9598673B2 · Ichim et al. · 2017 [cited by applicant]
US 20030069639A1 · Sander et al. · 2003 [cited by applicant]
US 20040229786A1 · Attawia · 2004 [cited by examiner]
US 20050118714A1 · Ha et al. · 2005 [cited by applicant]
US 20070065938A1 · Gronthos et al. · 2007 [cited by applicant]
US 20080260694A1 · Gronthos et al. · 2008 [cited by applicant]
US 20090088821A1 · Abrahamson et al. · 2009 [cited by applicant]
US 20100111910A1 · Rakoczy et al. · 2010 [cited by applicant]
US 20100203020A1 · Ghosh · 2010 [cited by applicant]
US 20120269774A1 · Ichim et al. · 2012 [cited by applicant]
AU 2006200478A1 · 2006 [cited by applicant]
WO WO1997018842A1 · 1997 [cited by applicant]
WO WO2001035968A1 · 2001 [cited by applicant]
WO WO2001080865A2 · 2001 [cited by applicant]
WO WO2002070030A1 · 2002 [cited by applicant]
WO WO2004084921A1 · 2004 [cited by applicant]
WO WO2004104166A2 · 2004 [cited by applicant]
WO WO2005049055A1 · 2005 [cited by applicant]
WO WO2005082433A1 · 2005 [cited by applicant]
WO WO2006032075A1 · 2006 [cited by applicant]
WO WO2006032092A1 · 2006 [cited by applicant]
WO WO2006108229A1 · 2006 [cited by examiner]
WO WO2006128100A2 · 2006 [cited by applicant]
WO WO2007087519A2 · 2007 [cited by applicant]
WO WO2007136673A2 · 2007 [cited by examiner]
WO WO2008036374A2 · 2008 [cited by applicant]
WO WO2008073631A2 · 2008 [cited by applicant]
WO WO2009018613A1 · 2009 [cited by applicant]
Acosta, Frank et al. The potential role of mesenchymal stem cell therapy for intervertebral disc degeneration: a critical overview. Neurosurg. Focus vol. 19 (3): E4. pp. 1-6. (Year: 2005). [cited by examiner]
Acosta, Frank et al., The potential role of mesenchymal stem cell therapy for intervertebral disc degeneration: a critical overview. Neurosurg. Focus vol. 19 (3): E4. pp. 1-6 (2005). [cited by applicant]
Alini et al. “Are animal models useful for studying human disc disorders/degeneration?” Eur Spine J 17(1): 2-19 (Jan. 2008). E-pub Jul. 14, 2007. [cited by applicant]
Chan et al. “Structure and Biology of the Intervertebral Disk in Health and Disease” Orthop Clin N Am 42(2011): 447-464. [cited by applicant]
Ganey, Timothy et al. A potential role for cell-based therapeutics in the treatment of intervertebral disc herniation. Eur Spine J (2002) 11 (Suppl. 2) : S206-S214. [cited by applicant]
Gronthos and Simmons. “The Growth Factor Requirements of STRO-1-Positive Human Bone Marrow Stromal Precursors Under Serum-Deprived Conditions in Vitro” Blood 85(4): 929-940 (Feb. 15, 1995). [cited by applicant]
Gronthos and Simmons et al. “Differential Cell Surface Expression of the STRO-1 and Alkaline Phosphatase Antigens on Discrete Developmental Stages in Primary Cultures of Human Bone Cells”, Journal of Bone and Mineral Re… [cited by applicant]
Gronthos et al. “Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow”. [cited by applicant]
Gronthos et al. “A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells” Stem Cells and Development 16:953-963 (May … [cited by applicant]
Herrera et al., “Exogenous Mesenchymal Stem Cells Localize to the Kidney by Means of CD44 Following Acute Tubular Injury”, Kidney International, 2007, 72: 430-441. [cited by applicant]
Liu et al. “Osteochondral Defect Repair with Autologous Bone Marrow-Derived Mesenchymal Stem Cells in an Injectable, In Situ, Cross-Linked Synthetic Extracellular Matrix”, Tissue Engineering, 2006, 12:3405-3416. [cited by applicant]
Murphy et al., “Stem Cell Therapy in a Caprine Model of Osteoarthritis”, Arthritis & Rheumatism, 2003, 48:3464-3474. [cited by applicant]
Otsuka et al., “Characterization of Osteoblastic Differentiation of Stromal Cells Line ST2 That is Induced by Absorbic Acid”, Am. J. Physiol. (Cell Physiol.), 1999, 46:C132-C138. [cited by applicant]
Radice et al., “Hyaluronan-based Biopolymers as Delivery Vehicles for Bone-marrow-derived Mesenchymal Progenitors”, J. Biome. Res. Materials, Part A., 1999, 50:101-109. [cited by applicant]
Kolf et al. “Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation” Arthritis Research and Therapy 9(1): 204 (Feb. 19, 2007). [cited by applicant]
Mwale et al. “Distinction between the extracellular matrix of the nucleus polposus and hyaline cartilage: a requisite for tissue engineering of intervertebral disc” European Cells and Materials 8: 58-64 (Dec. 15, 2004). [cited by applicant]
Sakai et al. “Transplantation of mesenchymal cells embedded in Atelocollagen gel to the intervertebral disc: a potential therapeutic model for disc degeneration” Biomaterials 24: 3531-3541 (Sep. 2003). [cited by applicant]
Sakai et al. “Differentiation of Mesenchymal Stem Cells Transplanted to a Rabbit Degenerative Disc Model” Spine 30(21): 2379-2387 (Nov. 1, 2005). [cited by applicant]
Samsonraj et al. “Establishing Criteria for Human Mesenchymal Stem Cell Potency” Stem Cells 33: 1878-1891 (Jun. 2015). [cited by applicant]
Simmons and Torok-Storb. “CD34 Expression by Stromal Precursors in Normal Human Adult Bone Marrow” Blood 78(11): 2848-2853 (Dec. 1, 1991). [cited by applicant]
Urban et al. “Nutrition of the Intervertebral Disc” Spine 29(23): 2700-2709 (Dec. 1, 2004). [cited by applicant]
Walker et al. “Molecular basis of intervertebral disc degeneration” The Spine Journal 4: 158S-166S (Nov.-Dec. 2004). [cited by applicant]
Crevensten et al. (2004) “Intervertebral Disc Cell Therapy for Regeneration: mesenchymal Stem Cell Implantation in Rat Intervertebral Discs”, Annals of Biomedical Engineering 32(3) : 430-34. [cited by applicant]
English Language Translation of a Final Notice of Preliminary Rejection issued on Jun. 27, 2018 by the Korean IP Office in connection with KR 10-2017-7024698. [cited by applicant]
Extended European Search Report issued Aug. 8, 2011, in connection with EP 09768629.9. [cited by applicant]
International Search Report issued by the International Searching Authority (ISA/US) on Aug. 21, 2009 in connection with PCT/AU2009/000817. [cited by applicant]
International Search Report issued by the International Searching Authority (ISA/US) on Sep. 26, 2008 in connection with PCT/AU2008/001137. [cited by applicant]
Written Opinion of the International Searching Authority issued Aug. 21, 2009 in connection with PCT/AU2009/000817. [cited by applicant]
International Preliminary Report on Patentability issued Jan. 5, 2011 in connection with PCT/AU2009/000817. [cited by applicant]
Office Action issued Jul. 11, 2012 in connection with U.S. Appl. No. 12/452,767. [cited by applicant]
Office Action issued Sep. 18, 2012 in connection with U.S. Appl. No. 12/452,767. [cited by applicant]
Office Action issued Feb. 12, 2013 in connection with U.S. Appl. No. 12/452,767. [cited by applicant]
Extended European Search Report issued Aug. 10, 2011 in connection with EP08782887.7. [cited by applicant]
Office Action issued Nov. 27, 2012 in connection with AU2008286244. [cited by applicant]
Office Action issued Dec. 16, 2011 in connection with CN 200980124157.2. [cited by applicant]
Office Action issued Dec. 4, 2012 in connection with CN 200980124157.2. [cited by applicant]
Acosta, F. et al., “The potential role of mesenchymal stem cell therapy for intervertebral disc degeneration: a critical overview”, Neurosurg. Focus, vol. 19, (Sep. 2005). [cited by applicant]
Sakai, D. et al., Transplantation of mesenchymal stem cells embedded in Atelocollagen gel to the intervertebral disc: a potential therapeutic model for disc degeneration, BioMaterials 24 (Mar. 2003). [cited by applicant]
Zhang, Y et al., “Bone Mesenchymal Stem Cells Transplanted into Rabbit Intervertebral Discs Can Increase Proteoglycans”, Clinical Orthopedics and Related Research, No. 430 (Aug. 2004). [cited by applicant]
Yamamoto, Y et al., “Upregulation of the Viability of Nucleus Pulposus Cells by Bone Marrow-Derived Stromal Cells”, Department of Orthopedic Surgery and Surgical Science, vol. 29 (Sep. 2003). [cited by applicant]
Kolf, C et al., “Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation”, BioMed Central Ltd, vol. 9 (Feb. 2007). [cited by applicant]
English language translation of Office Action, Apr. 1, 2024, issued in connection with Japanese Patent Application No. JP 2020-92260. [cited by applicant]